BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34011804)

  • 1. Tripartite Motif-Containing 44 is Involved in the Tumorigenesis of Laryngeal Squamous Cell Carcinoma, and its Expression is Downregulated by Nuciferine.
    Li QH; Sui LP; Zhao YH; Chen BG; Li J; Ma ZH; Hu ZH; Tang YL; Guo YX
    Tohoku J Exp Med; 2021 May; 254(1):17-23. PubMed ID: 34011804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of TRIM44 and its correlation with TLR4 in laryngeal squamous cell carcinoma.
    Bai J; Liu X; Zhang S; Dang S; Zhang Y; Zhang G
    Cell Mol Biol (Noisy-le-grand); 2022 Jun; 68(6):56-61. PubMed ID: 36227676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sesamin exerts anti-tumor activity in esophageal squamous cell carcinoma via inhibition of TRIM44 and NF-κB signaling.
    Wen L; Mao W; Xu L; Cai B; Gu L
    Chem Biol Drug Des; 2022 Jan; 99(1):118-125. PubMed ID: 34411455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4.
    Wei CY; Wang L; Zhu MX; Deng XY; Wang DH; Zhang SM; Ying JH; Yuan X; Wang Q; Xuan TF; He AQ; Qi FZ; Gu JY
    J Exp Clin Cancer Res; 2019 Mar; 38(1):137. PubMed ID: 30922374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of long non-coding RNA DUXAP8 suppresses proliferation, metastasis and EMT by modulating miR-498 through TRIM44-mediated AKT/mTOR pathway in non-small-cell lung cancer.
    Ji X; Tao R; Sun LY; Xu XL; Ling W
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3152-3165. PubMed ID: 32271433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of TRIM44 Inhibits the Proliferation and Invasion in Prostate Cancer Cells.
    Tan Y; Yao H; Hu J; Liu L
    Oncol Res; 2017 Sep; 25(8):1253-1259. PubMed ID: 28160462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.
    Zhou X; Yang Y; Ma P; Wang N; Yang D; Tu Q; Sun B; Xiang T; Zhao X; Hou Z; Fang X
    J Neurooncol; 2019 Nov; 145(2):211-222. PubMed ID: 31605296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of TRIM44 is related to invasive potential and malignant outcomes in esophageal squamous cell carcinoma.
    Kawaguchi T; Komatsu S; Ichikawa D; Hirajima S; Nishimura Y; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
    Tumour Biol; 2017 Jun; 39(6):1010428317700409. PubMed ID: 28618928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIM44 promotes cell proliferation and migration by inhibiting FRK in renal cell carcinoma.
    Yamada Y; Kimura N; Takayama KI; Sato Y; Suzuki T; Azuma K; Fujimura T; Ikeda K; Kume H; Inoue S
    Cancer Sci; 2020 Mar; 111(3):881-890. PubMed ID: 31883420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Novel Target of Colorectal Carcinoma: TRIM44 Regulates Cell Migration and Invasion via Activation of CXCR4/NF-κB Signaling.
    Kou T; Sha D; Wang F; He T; He X
    Cell Biochem Biophys; 2021 Mar; 79(1):113-121. PubMed ID: 33151473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of TRIM44 Inhibits Inflammation and Alleviates Traumatic Brain Injury in Rats by Downregulating TLR4-NF-κB Signaling.
    Zhu L; Dong C; Yue X; Ge P; Zheng G; Ye Z; Pan B
    Neuroimmunomodulation; 2022; 29(4):439-449. PubMed ID: 35609523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of TRIM44 mediates the NF-κB pathway to promote the progression of ovarian cancer.
    Yu Y; Li S; Sun J; Wang Y; Xie L; Guo Y; Li J; Han F
    Genes Genomics; 2024 Jun; 46(6):689-699. PubMed ID: 38691326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma.
    Kashimoto K; Komatsu S; Ichikawa D; Arita T; Konishi H; Nagata H; Takeshita H; Nishimura Y; Hirajima S; Kawaguchi T; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
    Cancer Sci; 2012 Nov; 103(11):2021-6. PubMed ID: 22862969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling.
    Kawabata H; Azuma K; Ikeda K; Sugitani I; Kinowaki K; Fujii T; Osaki A; Saeki T; Horie-Inoue K; Inoue S
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway.
    Xiong D; Jin C; Ye X; Qiu B; Jianjun X; Zhu S; Xiang L; Wu H; Yongbing W
    Cancer Sci; 2018 Oct; 109(10):3080-3092. PubMed ID: 30098109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIM44 facilitates ovarian cancer proliferation, migration, and invasion by inhibiting FRK.
    Yu XZ; Yuan JL; Ye H; Yi K; Qie MR; Hou MM
    Neoplasma; 2021 Jul; 68(4):751-759. PubMed ID: 34034495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuciferine Inhibits Oral Squamous Cell Carcinoma Partially through Suppressing the STAT3 Signaling Pathway.
    Xie JR; Chen XJ; Zhou G
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between tripartite motif-containing protein 44 protein expression and the prognosis of postoperative patients exhibiting skin squamous cell carcinoma.
    Wu J; Guo NZ; Cui LL; Wang W; Xiong CQ; Zhang XY
    Medicine (Baltimore); 2018 Nov; 97(44):e13021. PubMed ID: 30383661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIM31 promotes the progression of oral squamous cell carcinoma through upregulating AKT phosphorylation and subsequent cellular glycolysis.
    Sang SQ; Zhao YJ; Wang M; Zhong XQ; Yang ZC; Lu MM
    Neoplasma; 2023 Jun; 70(3):402-415. PubMed ID: 37498068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor.
    Yamada Y; Takayama KI; Fujimura T; Ashikari D; Obinata D; Takahashi S; Ikeda K; Kakutani S; Urano T; Fukuhara H; Homma Y; Inoue S
    Cancer Sci; 2017 Jan; 108(1):32-41. PubMed ID: 27754579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.